Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 12, 2007

View Archived Issues

Pharmacokinetics of GSK-221149A studied to prepare for clinical trial

C-reactive protein, neopterin correlate with PRTX-100 dose in healthy subjects

Antiinflammatory effects of the GABA-B agonist baclofen shown in mice

Recent Abbott patents describe new ACC inhibitors

Novel chemokine CCR5 receptor antagonists emerge from Roche R&D

Recent Bayer patent describes new agents for thromboembolic disorders

Alpharma obtains U.S. rights to Diractin from IDEA

Power3 Medical Products reports preliminary results of international validation study of PD test

Iomai begins phase I/II trial of immunostimulant patch with H5N1 influenza vaccine

Series C financing to fund Trophos' TRO-19622 and TRO-40303

Update on Pozen and AstraZeneca's PN-400 program

NeuroSearch begins phase II study of ABT-894 for neuropathic pain

Spectrum begins enrolling patients in second pivotal phase III trial of EOquin

OSI Prosidion reports results from metformin and PSN-9301 interaction study

IL-22 blockade shows benefit in mouse model of rheumatoid arthritis

Positive first-in-human trial results of novel endothelin antagonist from Actelion

Lilly launches Cialis for erectile dysfunction in Japan

Innogenetics to discontinue investment in candidate HCV E1 vaccine

Affymetrix enters into licensing agreement with Empire Genomics

Penwest and Otsuka enter into R&D agreement

FDA approves Adventrx clinical development plan for ANX-514

XTL Biopharmaceuticals begins phase IIb trial of bicifadine for diabetic neuropathic pain

Enrollment begins for CeNeS and Ergomed's phase II trial of CNS-5161 for cancer pain

Moberg Derma initiates enrollment of phase III trial of K-101 for onychomycosis

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026